S&P 500   4,030.88 (+0.70%)
DOW   32,687.12 (+0.39%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   198.42 (+0.43%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   99.86 (+4.10%)
T   18.62 (+0.43%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.50 (-0.39%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,030.88 (+0.70%)
DOW   32,687.12 (+0.39%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   198.42 (+0.43%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   99.86 (+4.10%)
T   18.62 (+0.43%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.50 (-0.39%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,030.88 (+0.70%)
DOW   32,687.12 (+0.39%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   198.42 (+0.43%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   99.86 (+4.10%)
T   18.62 (+0.43%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.50 (-0.39%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
S&P 500   4,030.88 (+0.70%)
DOW   32,687.12 (+0.39%)
QQQ   312.15 (+0.58%)
AAPL   160.71 (+0.90%)
MSFT   278.30 (+1.65%)
META   204.55 (+1.18%)
GOOGL   105.18 (+0.25%)
AMZN   100.87 (+0.26%)
TSLA   198.42 (+0.43%)
NVDA   272.85 (+4.15%)
NIO   9.32 (+0.54%)
BABA   84.61 (+1.09%)
AMD   99.86 (+4.10%)
T   18.62 (+0.43%)
F   11.78 (+0.51%)
MU   59.42 (+1.35%)
CGC   1.96 (-0.76%)
GE   91.89 (-0.31%)
DIS   96.86 (+0.33%)
AMC   4.54 (+2.95%)
PFE   40.50 (-0.39%)
PYPL   76.00 (-0.94%)
NFLX   301.96 (-1.25%)
NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

$90.98
-1.10 (-1.19%)
(As of 03/22/2023 02:33 PM ET)
Add
Compare
Today's Range
$90.57
$92.25
50-Day Range
$87.74
$117.27
52-Week Range
$70.73
$117.77
Volume
382,258 shs
Average Volume
1.59 million shs
Market Capitalization
$16.97 billion
P/E Ratio
122.95
Dividend Yield
N/A
Price Target
$120.11

BioMarin Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.61 Rating Score
Upside/​Downside
30.3% Upside
$118.15 Price Target
Short Interest
Bearish
3.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.94mentions of BioMarin Pharmaceutical in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$12.61 M Sold Last Quarter
Proj. Earnings Growth
164.10%
From $1.17 to $3.09 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

79th out of 983 stocks

Pharmaceutical Preparations Industry

23rd out of 478 stocks


BMRN stock logo

About BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

Why did Sarepta Therapeutics Stock Plummet? (BMRN)
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Why BioMarin Shares Are Plunging Today?
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down
Q4 2022 Biomarin Pharmaceutical Inc Earnings Call
BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates
Here's How BioMarin Stock Looks Ahead of Earnings
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Company Calendar

Last Earnings
10/26/2021
Today
3/22/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,082
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$118.15
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
+30.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.61
Research Coverage
19 Analysts

Profitability

Net Income
$141.56 million
Pretax Margin
7.14%

Debt

Sales & Book Value

Annual Sales
$2.10 billion
Cash Flow
$1.48 per share
Book Value
$24.82 per share

Miscellaneous

Free Float
183,265,000
Market Cap
$17.18 billion
Optionable
Optionable
Beta
0.39

Social Links


Key Executives

  • Jean-Jacques BienaiméJean-Jacques Bienaimé
    Chairman & Chief Executive Officer
  • Brian R. MuellerBrian R. Mueller
    Chief Financial Officer & Executive VP-Finance
  • Eduardo E. von Pervieux
    Chief Information Officer
  • Henry J. FuchsHenry J. Fuchs
    President-Worldwide Research & Development
  • Kevin Eggan
    Group VP, Head-Research & Early Development













BMRN Stock - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 1 sell rating, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price forecast for 2023?

19 Wall Street research analysts have issued 1 year price objectives for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $74.00 to $200.00. On average, they anticipate the company's share price to reach $118.15 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2023?

BioMarin Pharmaceutical's stock was trading at $103.49 on January 1st, 2023. Since then, BMRN shares have decreased by 11.0% and is now trading at $92.08.
View the best growth stocks for 2023 here
.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 7,280,000 shares, an increase of 7.9% from the February 13th total of 6,750,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is currently 4.9 days. Approximately 4.0% of the company's shares are sold short.
View BioMarin Pharmaceutical's Short Interest
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings data on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 3.73% and a net margin of 6.75%. The business's revenue was down 14.3% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2023 earnings guidance on Monday, February, 27th. The company provided EPS guidance of $1.80-$2.05 for the period, compared to the consensus EPS estimate of $1.61. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.58 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Norges Bank (1.48%), Geode Capital Management LLC (1.39%), Parnassus Investments LLC (1.26%), Charles Schwab Investment Management Inc. (0.67%), California Public Employees Retirement System (0.66%) and Legal & General Group Plc (0.63%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $92.08.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $17.18 billion and generates $2.10 billion in revenue each year. The biotechnology company earns $141.56 million in net income (profit) each year or $0.74 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

The company employs 3,082 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 3/22/2023 by MarketBeat.com Staff